Hunan FangSheng Pharmaceutical to Acquire JAK Inhibitor Patent Rights for RMB 80 Million
Hunan FangSheng Pharmaceutical Co., Ltd. (SHA: 603998) announced today that it has reached an agreement...
Haihe Biopharma Seeks Japan Approval for Risovalisib in PIK3CA-Mutated Ovarian Cancer
Haihe Biopharma Co., Ltd. has filed a market application with Japan’s Ministry of Health, Labour...
XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea’s leading pharmaceutical company, Dong-A...
Sino Biopharm’s LM-302 Shows Promising Results in Phase III Trials for Gastric Cancer
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that LM-302, an innovative antibody-drug conjugate (ADC) developed...
GoodRx and Novo Nordisk Introduce $499 Monthly Pricing for Semaglutide Pens
Goodrx Holdings Inc (NASDAQ: GDRX), the leading platform for medication savings in the U.S., has...
InnoCare Pharma’s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has unveiled its 2025 interim results, showcasing a...
China’s Zelgen Secures FDA IND Approval for Triple-Targeted Cancer Drug ZGGS34
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) and its subsidiary Gensun Biopharma Inc. announced...
Hansoh’s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six...
Sichuan Kelun-Biotech Reports H1 Revenue Drop, Advances Key Drug Commercialization
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) released its financial results for the first half...
WuXi Biologics Reports 16.1% Revenue Growth in H1 2025, Launches WuXiHigh 2.0 Platform
WuXi Biologics (Cayman) Inc. (HKG: 2269), a leading global Contract Research, Development and Manufacturing Organization...
RemeGen’s RC148 Granted Breakthrough Therapy Designation for NSCLC Treatment
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, announced that its novel...
Shandong Lukang’s CIGB-814 Starts Phase 1 Trial for Rheumatoid Arthritis Treatment
Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789) announced that its CIGB-814 immunomodulator has commenced a...
HutchMed Completes Patient Enrollment for Orpathys and Tagrisso Combination Study
Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient...
Sino Biopharmaceutical Reports 10.7% Revenue Growth and 140.2% Profit Surge in H1 2025
China-based Sino Biopharmaceutical Limited (HKG: 1177) announced its financial results for the first half of 2025....
Kangtai Biological Gains NMPA Approval for Trivalent Influenza Vaccine Clinical Trial
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that it has received approval from...
Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval
Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis,...
RemeGen Inks Licensing Deal With Santen China for RC28-E Eye Disease Drug
China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an agreement with Santen China, a...
MicroPort CardioFlow’s Alwide Plus Wins EU CE Mark for Heart Valve Procedures
China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), based in China, announced that its independently...
Mabwell’s Innovative CDH17-Targeted ADC 7MW4911 Receives FDA Clinical Trial Approval
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its self-developed CDH17-targeted antibody-drug conjugate...
Hengrui Pharma’s Hetrombopag Olamine Accepted by NMPA for Chemotherapy-Induced Thrombocytopenia
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the National Medical Products...